Advent International, a private equity firm based in Boston, Massachusetts, is considering a buyout deal for drugmaker Swedish Orphan Biovitrum.
Advent has approached other buyout firms including Permira in an attempt to lead a consortium for the acquisition of the Swedish biotech firm.
Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.
It is also weighing to bring in sovereign wealth funds for the bid. The talks are at an early stage, and it is not yet clear that they will ultimately lead to a deal, according to the people.
Source: Seeking Alpha
Can’t stop reading? Read more
Neuberger Berman closes $7.3bn private debt fund, surpassing target
Neuberger Berman closes $7.3bn private debt fund, surpassing target Neuberger Berman has announced...
Francisco Partners to buy majority stake in Genstar-backed OEConnection amid sector digitalisation
Francisco Partners to buy majority stake in Genstar-backed OEConnection amid sector digitalisation...
Partners Group and BBVA deepen ties with new evergreen fund for Spanish private banking clients
Partners Group and BBVA deepen ties with new evergreen fund for Spanish private banking clients...